Design and synthesis of a quinazolinone natural product-templated library with cytotoxic activity

Journal of Combinatorial Chemistry

Volumn 8, Issue 1, 2006, Pages 7-10

  Liu, Ji Feng ^a   Kaselj, Mira ^a   Isome, Yuko ^a   Ye, Ping ^a   Sargent, Katie ^a   Sprague, Kevin ^a   Cherrak, Djamel ^a   Wilson, Christopher J ^a   Si, Ying ^a   Yohannes, Daniel ^a   Ng, Shi Chung ^a  

^a ARQULE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANIMAL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; HUMAN; IC 50; SYNTHESIS; TUMOR CELL LINE;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; QUINAZOLINES;

EID: 31544457663     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc050108g     Document Type: Article

References (35)

1. For recent reviews on quinazoline alkaloids, see: (a) Michael, J. P. Nat. Prod. Rep. 2004, 21, 650.
2. (b) Johne, S. In Rodd's Chemistry of Carbon Compounds; Ansell, M. F., Ed.; Supplements to the 2nd ed.; Elsevier: Amsterdam, 1995; Vol. IV I/J, pp 223-240.
3. (c) D'yakonov, A. L.; Telezhenetskaya, M. V. Chem. Nat. Comput. 1997, 33, 221.
4. (a) Ma, Z. Z.; Hano, Y.; Nomura, T.; Chen, Y. J. Heterocycles 1999, 51, 1883.
5. (b) Ma, Z. Z.; Hano, Y.; Nomura, T.; Chen, Y. J. Bioorg. Med. Chem. Lett. 2004, 14, 1193.
6. (a) Ma, Z.; Hano, Y.; Nomura, T.; Chen, Y. Heterocycles 1997, 46, 541.
7. (b) Cagir, A.; Jones, S. H.; Gao, R.; Eisenhauer, B. M.; Hecht, S. M. J. Am. Chem. Soc. 2003, 125, 13628.
8. (c) Cagir, A.; Jones, S. H.; Eisenhauer, B. M.; Gao, R.; Hecht, S. M. Bioorg. Med. Chem. Lett. 2004, 14, 2051.
9. (a) Numata, A.; Takahashi, C.; Matsushita, T.; Miyamoto, T.; Kawai, K.; Usami, Y.; Matsumura, E.; Inoue, M.; Ohishi, H.; Shingu, T. Tetrahedron Lett. 1992, 33, 1621.
10. (b) Takahashi, C.; Matsushita, T.; Doi, M.; Minoura, K.; Shingu, T.; Kumeda, Y.; Numata, A. J. Chem. Soc., Perkin Trans. 1 1995, 2345.
11. Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893.
12. For example, Raltitrexed (Tomudex, marketed for colorectal cancer), Ispinesib (phase II for solid tumors), and Tempostatin (phase II for bladder cancer).
13. Liu, J.-F.; Lee, J.; Dalton, A. M.; Bi, G.; Yu, L.; Baldino, C. M.; McElory, E.; Brown, M. Tetrahedron Lett. 2005, 46, 1241.
14. Liu, J.-F.; Ye, P.; Zhang, B.; Bi, G.; Sargent, K.; Yu, L.; Yohannes, D.; Baldino, C. M. J. Org. Chem. 2005, 70, 6339.
15. Liu, J.-F.; Ye, P.; Sprague, K.; Sargent, K.; Yohannes, D.; Baldino, C. M.; Wilson, C. J.; Ng, S.-C. Org. Lett. 2005, 7, 3363.
16. Liu, J.-F.; Kaselj, M.; Isome, Y.; Chapnick, J.; Zhang, B.; Bi, G.; Yohannes, D.; Yu, L.; Baldino, C. M. J. Org. Chem. 2005, 70, 10488.
17. (a) Liu, J.-F.; Ye, P.; Sargent, K.; Sprague, K.; Cherrak, D.; Yohannes, D.; Baldino, C. M. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, March 13-17, 2005, ORGN-213.
18. (b) Liu, J.-F.; Ye, P.; Kaselj, M.; Sprague, K.; Sargent, K.; Isome, Y.; Zhang, B.; Bi, G.; Yohannes, D.; Yu, L.; Baldino, C. M. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, March 13-17, 2005 2005, ORGN-409.
19. (c) Liu, J.-F.; Wilson, C. J.; Ye, P.; Sprague, K.; Sargent, K.; Si, Y.; Beletsky, G.; Yohannes, D.; Ng, S.-C. Biorg. Med. Chem. Lett. 2006, in press.
20. Wilson, C. J.; Si, Y.; Thompson, C. M.; Smellie, A.; Ashwell, M.; Liu, J.-F.; Ye, P.; Yohannes, D.; Ng, S.-C. J. Biomol. Screening 2005, in press. MTS assay was performed as described in Promega Technical Bulletin No. 169 (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay, http://www.promega.com/; Website accessed July 28, 2005.). The assay uses the novel tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and the electron coupling reagent phenazine methosulfate (PMS). MTS is chemically reduced by cells into formazan, which is soluble in tissue culture medium. The measurement of the absorbance of the formazan can be carried out using 96-well microplates at 492 nm. The assay measures dehydrogenase enzyme activity found in metabolically active cells.
21. 2-Aryl and 2-styrylquinazolin-4(3H)-ones have been reported to be cytotoxic agents that inhibit tubulin polymerization. See: (a) Raffa, D.; Edler, M. C.; Daidone, G.; Maggio, B.; Merikech, M.; Plescia, S.; Schillaci, D.; Bai, R.; Hamel, E. Eur. J. Med. Chem. 2004, 39, 299.
22. (b) Xia, Y.; Yang, Z.-Y.; Hour, M.-J.; Kuo, S.-C.; Xia, P.; Bastow, K. F.; Nakanishi, Y.; Nampoothiri, P.; Hackl, T.; Hamel, E.; Lee, K. H. Bioorg. Med. Chem. Lett. 2001, 11, 1193.
23. (c) Jiang, J. B.; Hesson, D. P.; Dusak, B. A.; Dexter, D. L.; Kang, G. J.; Hamel, E. J. Med. Chem. 1990, 33, 1721.
24. 2-Styrylquinazolin-4-ones also showed other biological significances, such as being useful as AMPA receptor antagonists, an antitrypanosomal agent, and anticonvulsant. See: (a) Chenard, B. L.; Welch, W. M.; Blake, J. F.; Butler, T. W.; Reinhold: A.; Ewing, F. E.; Menniti, F. S.; Pagnozzi, M. J. J. Med. Chem. 2001, 44, 1710.
25. (b) Keiser, J.; Burri, C. Trop. Med. Int. Health 2001, 6, 369.
26. (c) Welch, W. M.; Ewing, F. E.; Huang, J.; Menniti, F. S.; Pagnozzi, M. J.; Kelly, K.; Seymour, P. A.; Guanowsky, V.; Guhan, S.; Guinn, M. R.; Critchett, D.; Lazzaro, J.; Ganong, A. H.; DeVries, K. M.; Staigers, T. L.; Chenard, B. L. Bioorg. Med. Chem. Lett. 2001, 177.
27. (d) Kacker, I. K.; Zaheer, S. H. J. Indian Chem. Soc. 1951, 28, 344.
28. Both mackinazolinone (5) and isaindigotone (6) only demonstrated cytotoxicity at > 100 μM concentrations in the selected cancer cell lines in the MTS assay described above. For primary screening, our activity cutoff was ≤50 μM.
29. The in-house-developed library design tool we employed, MAPMAKER, has been described; see: (a) Li, D.; Rotstein, S. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, August 22-26, 2004, CINF-98.
30. (b) Baldino, C. M.; Caserta, J.; Goetzinger, W. K.; Harris, M.; Hartsough, D.; Yohannes, D.; Yu, L.; Kyranos, J. N. Curr. Drug Discovery 2004, 7, 15.
31. For the design of libraries possessing maximal information, content, and diversity, see: Patterson, J. E.; Zhang, Y.; Smellie, A.; Li, D.; Hartsough, D. S.; Yu, L.; Baldino, C. M. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, March 13-17, 2005, CINF-75.
32. We employed a Biotage Smith Synthesizer integrated into the ArQule AMAP high-throughput parallel chemistry platform.
33. The purification of crude products were performed on the Preparative HPLC. The preparative HPLCs were conducted using a ProntoSIL 120-10-C18 column (50 × 20 mm). The flow rate was at 40 mL/min utilizing an acetonitrile/water mobile phase and 0.1% trifluoroacetic acid as a modifier with mass-triggered fraction collection. The crude and purified products were characterized by LC/MS with an integrated LC/MS system of a Shimadzu LC instrument and Micromass DMZ MS instrument. The HPLC was conducted using a Zorbax SB-C8 column (4.6 × 30 mm 3.5μm) with a flow rate at 3.0 mL/min, an acetonitrile/water mobile phase, and 0.05% trifluoroacetic acid as a modifier. For detailed information, see: (a) Kyranos, J. N.; Cai, H.; Zhang, B.; Goetzinger, W. K. Curr. Opin. Drug Discovery Dev. 2001, 4, 719.
34. (b) Goetzinger, W.; Zhang, X.; Bi, G.; Towle, M.; Cherrak, D.; Kyranos, J. N. Int. J. Mass. Spectrom. 2004, 238, 153.
35. The three cancer cell lines represent diverse tissue sources. Two sets of assays (n = 2) were run with 20 data points using Taxol as a positive control.